Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 14, 2013; 19(38): 6383-6397
Published online Oct 14, 2013. doi: 10.3748/wjg.v19.i38.6383
Published online Oct 14, 2013. doi: 10.3748/wjg.v19.i38.6383
Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies
Michael Luis, António Araújo, Ramon Andrade de Mello, Gastrointestinal Unit, Service of Medical Oncology, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Michael Luis, Ana Tavares, Lúcio Lara-Santos, Gastrointestinal Unit, Experimental Pathology and Therapeutics Group, Research Center-Portuguese Oncology Institute, 4200-072 Porto, Portugal
Liliana S Carvalho, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
Liliana S Carvalho, Institute of Cellular and Molecular Biology, 4150-180 Porto, Portugal
Lúcio Lara-Santos, Gastrointestinal Unit, Section of Surgical Oncology, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Ramon Andrade de Mello, Department of Medicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
Author contributions: All authors contributed as the same for this manuscript preparation.
Correspondence to: Ramon Andrade de Mello, MD, PhD, Professor, Gastrointestinal Unit, Service of Medical Oncology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ramondemello@gmail.com
Telephone: +351-2250-84000-7323 Fax: +351-2250-84010
Received: July 9, 2013
Revised: July 24, 2013
Accepted: August 5, 2013
Published online: October 14, 2013
Processing time: 98 Days and 13.5 Hours
Revised: July 24, 2013
Accepted: August 5, 2013
Published online: October 14, 2013
Processing time: 98 Days and 13.5 Hours
Core Tip
Core tip: Advanced gastric cancer is a very aggressive disease thought the standard chemotherapy protocols available. In 2010, Trastuzumab for Gastric Cancer trial showed that the combination of trastuzumab, could be considered a new standard option for patients with human epidermal growth factor receptor 2 (HER2) positive advanced gastric and gastro-esophageal junction cancer. Thus, a new era emerged for those patients due to the interesting possibility in prolong survival in a personalized setting (HER2 positive). Our manuscript will provide an overview of the molecular mechanisms involved and also promising targeted therapies in this field.